UK-based MiNA Therapeutics has entered into a research collaboration agreement with AstraZeneca to assess small activating RNA (saRNA) molecules in metabolic diseases.

The companies will carry out in vitro and in vivo studies to support the development of saRNA therapeutics for treating metabolic diseases.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The collaboration seeks to leverage MiNA’s expertise in saRNA therapeutics and AstraZeneca’s knowledge of metabolic disease treatment to conduct preclinical research.

MiNA CEO Robert Habib said: “Many metabolic diseases lack sufficient treatment options to help patients manage their disease and to treat the underlying causes to improve patient outcomes.

“This is an exciting opportunity for us to collaborate with AstraZeneca, a global leader in the discovery and development of prescription medicines to treat metabolic diseases, that may lead to therapeutic advances for a large number of patients globally.”

Once the studies are complete, AstraZeneca may also advance to licence the programme to support further development enabling saRNA molecules to target an undisclosed gene.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AstraZeneca New Modalities, Discovery Sciences, R&D chief scientist Shalini Andersson said: “saRNA molecules are a novel therapeutic modality that upregulate genes and have the potential to access disease-relevant targets that cannot be addressed efficiently with other approaches.

“We look forward to working with MiNA to investigate the potential of saRNAs further.”

Recently, AstraZeneca secured the US Food and Drug Administration (FDA) priority review for Farxiga (dapagliflozin) to treat heart failure with reduced ejection fraction (HFrEF).